WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406131
CAS#: 880635-03-0
Description: GW6471 is a PPAR α antagonist (IC50 = 0.24 μ M). GW6471 enhances the binding affinity of the PPAR α ligand-binding domain to the co-repressor proteins SMRT and NCoR.
MedKoo Cat#: 406131
Name: GW6471
CAS#: 880635-03-0
Chemical Formula: C35H36F3N3O4-
Exact Mass: 619.26634
Molecular Weight: 619.67
Elemental Analysis: C, 67.84; H, 5.86; F, 9.20; N, 6.78; O, 10.33
Synonym: GW6471; GW-6471; GW 6471
IUPAC/Chemical Name: (S,Z)-N-(3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-((4-oxo-4-(4-(trifluoromethyl)phenyl)but-2-en-2-yl)amino)propyl)propionamide
InChi Key: TYEFSRMOUXWTDN-DYQICHDWSA-N
InChi Code: InChI=1S/C35H36F3N3O4/c1-4-33(43)39-22-29(40-23(2)20-32(42)26-12-14-28(15-13-26)35(36,37)38)21-25-10-16-30(17-11-25)44-19-18-31-24(3)45-34(41-31)27-8-6-5-7-9-27/h5-17,20,29,40H,4,18-19,21-22H2,1-3H3,(H,39,43)/b23-20-/t29-/m0/s1
SMILES Code: CCC(NC[C@@H](N/C(C)=C\C(C1=CC=C(C(F)(F)F)C=C1)=O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)=O
Appearance: Solid powder
Purity: >98%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 619.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Ambrosino P, Soldovieri M, Russo C, Taglialatela M. Activation and Desensitization of Trpv1 Channels in Sensory Neurons by the Peroxisome Proliferator-Activated Receptor α Agonist Palmitoylethanolamide. Br J Pharmacol. 2012 Oct 19. doi: 10.1111/bph.12029. [Epub ahead of print] PubMed PMID: 23083124.
2: Cai J, Sun L, Lin B, Wu M, Qu J, Snider BJ, Wu S. Pretreatment with proteasome inhibitors protects against oxidative injuries via PPARα-dependent and -independent pathways in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2012 Aug 31;53(9):5967-74. doi: 10.1167/iovs.12-10048. PubMed PMID: 22879419.
3: Downer EJ, Clifford E, Amu S, Fallon PG, Moynagh PN. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α. J Biol Chem. 2012 Jul 20;287(30):25440-53. doi: 10.1074/jbc.M112.371757. Epub 2012 May 31. PubMed PMID: 22654113; PubMed Central PMCID: PMC3408184.
4: Kumar A, Qiao Z, Kumar P, Song ZH. Effects of palmitoylethanolamide on aqueous humor outflow. Invest Ophthalmol Vis Sci. 2012 Jul 3;53(8):4416-25. doi: 10.1167/iovs.11-9294. PubMed PMID: 22589443.
5: Ruiz-Medina J, Flores JA, Tasset I, Tunez I, Valverde O, Fernandez-Espejo E. Alteration of neuropathic and visceral pain in female C57BL/6J mice lacking the PPAR-α gene. Psychopharmacology (Berl). 2012 Aug;222(3):477-88. doi: 10.1007/s00213-012-2662-8. Epub 2012 Feb 22. PubMed PMID: 22354556.
6: Yu X, Li X, Zhao G, Xiao J, Mo Z, Yin K, Jiang Z, Fu Y, Zha X, Tang C. OxLDL up-regulates Niemann-Pick type C1 expression through ERK1/2/COX-2/PPARα-signaling pathway in macrophages. Acta Biochim Biophys Sin (Shanghai). 2012 Feb;44(2):119-28. doi: 10.1093/abbs/gmr119. Epub 2012 Jan 9. PubMed PMID: 22232299.
7: Reyes-Cabello C, Alen F, Gómez R, Serrano A, Rivera P, Orio L, RodrÃguez de Fonseca F, Pavón FJ. Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration. Pharmacol Biochem Behav. 2012 Mar;101(1):1-7. doi: 10.1016/j.pbb.2011.11.011. Epub 2011 Nov 22. PubMed PMID: 22133635.
8: Kämmerer I, Ringseis R, Biemann R, Wen G, Eder K. 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages. Lipids Health Dis. 2011 Nov 30;10:222. doi: 10.1186/1476-511X-10-222. PubMed PMID: 22129452; PubMed Central PMCID: PMC3248880.
9: Müller MQ, Sinz A. Chemical cross-linking and high-resolution mass spectrometry to study protein-drug interactions. Methods Mol Biol. 2012;803:205-18. doi: 10.1007/978-1-61779-364-6_14. PubMed PMID: 22065227.
10: Takano M, Otsuka F, Matsumoto Y, Inagaki K, Takeda M, Nakamura E, Tsukamoto N, Miyoshi T, Sada KE, Makino H. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α. Mol Cell Endocrinol. 2012 Jan 2;348(1):224-32. doi: 10.1016/j.mce.2011.08.027. Epub 2011 Aug 25. PubMed PMID: 21888945.
